HCW Biologics targets first-half 2027 IND filing for solid-tumor candidate

On October 9, 2026, HCW Biologics said it remains on track to file an Investigational New Drug (IND) application in the first half of 2027 for HCW11-018b, its lead T-cell engager candidate for solid tumors.

The company said a recent FDA Type B meeting provided guidance on preparing the application for a planned first-in-human cancer study.

Manufacturing of current Good Manufacturing Practice (cGMP) material for clinical trials is underway.

HCW11-018b is part of HCW Biologics’ second-generation, non-Fc-based T-cell engager program and uses its proprietary TRBC platform. The announcement reports development progress—not human trial results.

Sources:

Release Details - HCW Biologics, Inc.

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

HCW Biologics, Inc.: Investor Relations

HCW Biologics on track for 1H 2027 cancer IND filing

HCW Biologics (HCWB) Stock News & Updates

HCW Biologics receives FDA guidance for cancer drug trial

HCWB Stock Price, News & Analysis

Release Details - HCW Biologics, Inc.

HCW Biologics Maintains Momentum Toward Compl

HCWB Press Releases HCW Biologics

HCW Biologics (HCWB) FDA Approvals

HCW Biologics (Nasdaq:HCWB) - Stock Analysis - Simply Wall St

HCW Biologics Reports FDA Type B Meeting Guidance for ...

HCW Biologics receives FDA guidance for cancer drug trial By Investing.com

HCW Biologics Inc. Stock Price: Quote, Forecast, Splits & ...